Bernstein still likes Live Nation, lawsuit and all

Same tour, new price tag

Bernstein SocGen Group is keeping the faith on Live Nation Entertainment, reiterating an Outperform rating and a $200 price target. That’s a polite Wall Street way of saying: the show is still on, and the seats may not be full-priced yet.

But there’s always a backstage pass to litigation

Here’s the catch. Bernstein also updated its model to include an extra $150 million in litigation contingencies, reflecting the expected adverse ruling in the antitrust case. In other words, this isn’t a clean victory lap — it’s more like a headliner performing while the fire marshal is still asking questions.

Why investors should care

Live Nation’s stock has already had a strong run, and a bullish rating from Bernstein can help keep momentum alive. But the legal overhang matters because even a fan-favorite business can get dinged if the courtroom costs keep stacking up.

The big picture

For now, Bernstein is basically saying Live Nation’s core touring engine still has juice, and the valuation leaves some upside on the table. But if you own the stock, you’re not just buying concert demand — you’re also signing up for the antitrust soap opera.